Business Context and Reporting Period
Rosecliff Acquisition Corp I filed this Form 8-K on April 11, 2023, announcing a proposed business combination with Spectral MD Holdings, Ltd. (“Spectral MD”). The transaction would involve a two-step merger under which Spectral MD would become a wholly owned subsidiary and then merge into a wholly owned subsidiary of Rosecliff.
The filing is primarily a transaction announcement under Regulation FD and does not report a quarterly or annual operating period. The filing registrant is Rosecliff Acquisition Corp I; the provided source does not identify “Spectral AI, Inc.” as the registrant.
Financial and Operating Metrics
- The filing does not provide clear values for revenue, profit, cash flow, margins, debt, liquidity, valuation, or other operating metrics.
- The filing does not include financial statements or a quantitative transaction consideration summary.
- Rosecliff’s registered securities included units, Class A common stock, and redeemable warrants listed on Nasdaq.
Material Changes Versus Prior Period
No comparable-period financial information or operating changes are reported. The material event is the execution of the Business Combination Agreement on April 11, 2023.
Guidance, Outlook, Risks, and Unusual Items
- The parties stated that Rosecliff intended to file a Form S-4 registration statement containing a proxy statement/prospectus. Stockholder approval and other transaction conditions remained outstanding.
- The filing does not provide formal financial guidance or a clear transaction completion date.
- Key risks include failure to complete the transaction, failure to meet the business combination deadline or obtain an extension, failure to satisfy stockholder and regulatory approval conditions, termination rights, possible Nasdaq listing noncompliance, financing and capital-raising needs, litigation, business disruption, market volatility, economic conditions, and changes in the regulatory environment.
- The filing notes that no third-party valuation was obtained in determining whether to pursue the proposed transaction.
- The announcement and related exhibit were furnished, rather than filed, for purposes of Section 18 liability and incorporation by reference.
- The filing contains forward-looking statements and cautions investors not to rely on them as guarantees or predictions.
Investor Verification Checklist
- Verify the final Form S-4, proxy statement/prospectus, transaction consideration, ownership structure, and any proposed financing.
- Review audited financial statements and pro forma financial information for Spectral MD and the combined company.
- Confirm required stockholder, regulatory, and other closing approvals, as well as any business combination deadline or extension.
- Assess redemption levels, available cash, dilution from warrants or other securities, and post-closing capital requirements.
- Confirm Nasdaq listing compliance and the final trading symbol and capital structure.
- Review the definitive transaction documents and any amendments, termination provisions, litigation, and updated risk factors.